Popular filter options for stargardt disease trials
Age-Related Macular Degeneration Clinical Trials
View 11 Age-Related Macular Degeneration medical studies.
Behavioural Intervention
Scotoma Awareness Training for Low Vision
This trial will test if a new method of electrical stimulation can help people with low vision see better. The treatment is relevant to public health because it has the potential to improve the lives of millions of people suffering from low vision.
Brain Stimulation
Active tDCS for Age-Related Macular Degeneration
This trial is testing whether a-tDCS, a kind of brain stimulation, can be combined with perceptual learning to improve the ability of people with age-related or juvenile macular degeneration to read words on a computer screen.
AMD Clinical Trials
View 11 AMD medical studies.
Behavioural Intervention
Scotoma Awareness Training for Low Vision
This trial will test if a new method of electrical stimulation can help people with low vision see better. The treatment is relevant to public health because it has the potential to improve the lives of millions of people suffering from low vision.
Brain Stimulation
Active tDCS for Age-Related Macular Degeneration
This trial is testing whether a-tDCS, a kind of brain stimulation, can be combined with perceptual learning to improve the ability of people with age-related or juvenile macular degeneration to read words on a computer screen.
ABCA4 Positive Clinical Trials
View 6 ABCA4 positive medical studies.
Vitamin A Derivative
ALK-001 for Stargardt Disease
This trial is looking at the long-term safety and effects of a retinal drug for people with Stargardt disease, a rare genetic disorder that causes vision loss. The study is an extension of a previous trial, enrolling participants who are at least 8 years old.
Vitamin A Derivative
ALK-001 for Stargardt Disease
This trial is exploring the long term safety and effectiveness of a treatment for Stargardt disease, a genetic disorder that causes vision loss. The treatment, ALK-001 (C20-D3-retinyl acetate), is being given to patients 8 to 70 years old to see if it slows the progression of the disease. The trial is funded by the FDA's Office of Orphan Products Development.
Stargardt Disease Clinical Trials With No Placebo
View 18 stargardt disease medical studies that do not have a placebo group.
Behavioural Intervention
Scotoma Awareness Training for Low Vision
This trial will test if a new method of electrical stimulation can help people with low vision see better. The treatment is relevant to public health because it has the potential to improve the lives of millions of people suffering from low vision.
Frequently Asked Questions
Introduction to stargardt disease
What are the top hospitals conducting stargardt disease research?
When it comes to advancing research and treatment options for Stargardt disease, several hospitals are leading the way. In Hagerstown, Cumberland Valley Retina Consultants has made significant strides with four active trials dedicated to this rare condition. Over the years, they have conducted a total of 16 trials since their first recorded investigation in 2012. Similarly, in Dallas, the Retina Foundation of the Southwest is actively engaged in four ongoing stargardt disease trials. With a history that dates back to their initial trial in 2012, they have completed an impressive tally of 20 studies related to this degenerative eye disorder.
Meanwhile, at Retina Consultants of Texas located in Bellaire and Retina Research Institute of Texas situated in Abilene—both renowned institutions—are also contributing significantly to the field of stargardt disease research. Each hospital currently conducts four active clinical trials focused on understanding and combating this genetic condition. Having embarked on their first stargardt disease trial more recently (in Bellaire's case dating back only to 2015), these hospitals have already achieved remarkable milestones by conducting a combined total of 24 and 34 trials respectively.
Notably last but certainly not least,making valuable contributions from East Florida Eye Institute based out Stuart,the establishment carrying three concurrent clinical tests intended towards fighting against Stargart diseases.It interestingly stood as one among those few pioneers who accomplished eleven previous investigations into such cases;dating its roots all way long ago till2005.
These leading hospitals across different locations showcase their commitment and dedication towards tackling Stargardt disease—a condition that affects individuals' central vision as a result of genetic mutations.With each new trial initiated,and with every advancement made,the hope for improved treatments grows brighter.The collective efforts being undertaken by these medical centers pave the path toward potential breakthroughs,serving as beacons for patients worldwide affected by this challenging disease
Which are the best cities for stargardt disease clinical trials?
When it comes to stargardt disease clinical trials, several cities have emerged as key hubs for research and innovation. Phoenix, Arizona, Dallas, Texas, Salt Lake City, Utah, Portland Oregon, and Gainesville Florida are among the top locations offering active trials in this field. These cities are conducting studies on various potential treatments such as IONIS-FB-LRx, Zimura, Avacincaptad pegol 2 mg intravitreal injection and Tinlarebant among others. With their commitment to advancing knowledge and finding effective therapies for stargardt disease sufferers, these cities provide invaluable opportunities for participation in groundbreaking clinical trials.
Which are the top treatments for stargardt disease being explored in clinical trials?
The search for effective treatments for Stargardt disease is ongoing, with several potential options being explored in clinical trials. Leading the pack is ALK-001, currently involved in two active trials specifically targeting Stargardt disease. This innovative treatment made its first appearance on the medical landscape in 2015 and has since garnered a total of two dedicated trials. Additionally, there are promising developments involving avacincaptad pegol 2 mg intravitreal injection and 'Scotoma awareness' training, both new entries to the field with one active trial each. These cutting-edge approaches offer hope for individuals living with Stargardt disease as researchers continue their quest for effective interventions.
What are the most recent clinical trials for stargardt disease?
Promising developments are arising in the field of Stargardt disease, with recent clinical trials offering hope for patients. One such trial involves an experimental treatment utilizing low doses, aiming to assess its effectiveness and safety in treating this condition. Another study focuses on Part 1 of a larger trial targeting Stargardt disease specifically. Additionally, researchers are investigating the potential benefits of JNJ-81201887 at higher doses as a therapeutic option for this debilitating disease. A Phase 3 trial is also underway, evaluating the efficacy and safety of Avacincaptad pegol through intravitreal injection. Lastly, gene therapy using vMCO-010 exhibits promise as it progresses through Phase 2 trials. These innovative approaches hold significant potential for improving outcomes and quality of life for individuals affected by Stargardt disease.
What stargardt disease clinical trials were recently completed?
Several clinical trials for Stargardt disease, a debilitating inherited eye disorder, have recently concluded. In May 2022, Sandoz completed a trial investigating the potential of SOK583A1 to address this condition. Similarly, Kodiak Sciences Inc wrapped up their KSI-301 study in June 2021. Additionally, Maturi Raj K., M.D., P.C., finished their RBM-007 Injectable Solution trial in the same month. These milestones highlight the ongoing efforts to find effective treatments for Stargardt disease and bring hope to those impacted by this progressive visual impairment.